Oncology
Guidelines, trial intelligence, mechanisms and education across oncology practice, from tumour-specific updates to systemic anticancer therapy evidence.
Latest Guidelines
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment
Trastuzumab deruxtecan is recommended as an option for HER2-positive unresectable or metastatic breast cancer only after 1 or more prior lines of anti-HER2 treatment—use in treatment-naïve…
Nirogacestat for treating desmoid tumours
Nirogacestat is recommended as an option for treating desmoid tumours in adults when surgery is not suitable or has failed, enabling consideration of this gamma-secretase inhibitor…
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients who progress after prior…
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable
Ibrutinib combined with R-CHOP is recommended for untreated mantle cell lymphoma patients who are fit enough to undergo stem cell transplantation, offering improved outcomes compared to…
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based on individual patient factors…
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing prior to dostarlimab consideration,…
Trial Radar
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BT8009-100 Trial Summary First-in-human trial testing BT8009 alone and with pembrolizumab in advanced cancers expressing Nectin-4 protein.
PHASE3A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Belzutifan compared to everolimus for advanced kidney cancer, testing if belzutifan improves survival and delays disease progression.
PHASE2Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy…
TrialDevelopment and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic Test
Background and Study Aims: Melanoma is the most dangerous form of skin cancer, and early detection is crucial…
Clinical News
Pope discharged from hospital days after lung cancer surgery
Rapid post-operative recovery and discharge following lung cancer surgery is achievable in selected patients, even in elderly individuals…
16 Oct 2026Pope pictured for first time since surgery and cancer diagnosis
Pope Francis underwent lung cancer surgery at Gemelli Hospital in Rome; public appearance marks recovery milestone following diagnosis…
16 Oct 2026Teen’s death inspires mum’s drive for earlier rare cancer diagnosis
Soft tissue sarcomas in teenagers are being diagnosed late, prompting new diagnostic guidance to improve early recognition and…
15 Oct 2026Emotional TV plea for cancer research leads to meeting with PM
UK government announces new measures for brain cancer care following advocacy by patient Archie Goodburn, signalling potential policy…
Relevant Mechanisms
BRAF/MEK Pathway — Melanoma
BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals…
MechanismBTK Inhibition — B-cell Malignancies
BTK Inhibition — B-cell Malignancies is a clinically relevant Drug Science explainer. Bruton's tyrosine kinase (BTK) is a non-receptor cytoplasmic…
MechanismCDK4/6 Inhibition — Breast Cancer
CDK4/6 Inhibition — Breast Cancer is a clinically relevant Drug Science explainer. Cell cycle progression from G1 to S phase…
MechanismEGFR Pathway
EGFR Pathway is a clinically relevant Drug Science explainer. The epidermal growth factor receptor (EGFR/ErbB1/HER1) is a transmembrane receptor tyrosine…
MechanismHER2 Signalling
HER2 Signalling is a clinically relevant Drug Science explainer. Human epidermal growth factor receptor 2 (HER2/ErbB2) is a receptor tyrosine…
CPD, Podcasts & Webinars
No specialty-tagged education live yet
Oncology education appears here when podcasts, webinars and CPD modules are tagged to this hub.
Useful starting points in Oncology
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BT8009-100 Trial Summary First-in-human trial testing BT8009 alone and with pembrolizumab in advanced cancers expressing Nectin-4 protein.
TrialA Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Belzutifan compared to everolimus for advanced kidney cancer, testing if belzutifan improves survival and delays disease progression.
TrialEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy…
Education that still supports this area
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
WebinarJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
WebinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
Follow Oncology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Oncology
Choose guideline, trial, Drug Science and education updates for this specialty.